ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1397

Changes In MMP In Fibroblast-Like Synoviocytes Following Adipogenesis

Satoshi Yamasaki, Kazuhiko Kumagai, Kouji Endo, Takaki Nojima and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Adipocytokines, matrix metalloproteinase (MMP), mesenchymal stem cells and synovial cells, synovial fluid

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Fibroblast-like synovial cells (FLS) play important roles in the disease progression of RA. FLS produce cytokines and chemokines that contribute to chronic inflammation of RA-affected joints. They also secrete matrix metalloproteinases (MMPs) that cause degradation of joint tissues, including bone and cartilages, which leads to severe structural destruction of inflamed joints. We previously reported that the production of IL-6, a cytokine that contributes to the progression of RA, by FLS is reduced by adipogenesis induction. Therefore, we predict that induction of FLS adipogenesis could be a new therapeutic strategy to treat RA. Our objective in this study was to examine whether MMPs production in FLS could be altered by adipogenesis induction.  

Methods:   FLS were isolated from the synovial tissues by enzymatic digestion. MSC were purchased from Lonza (Walkersville, USA). Adipogenesis of FLS was carried out by using the MSC adipogenic differentiation medium BulletKit (Lonza), according to the manufacturer’s instructions. The mRNA expression levels of MMPs and tissue inhibitors of metalloproteinases (TIMPs) were evaluated by DNA array (SurePrint G3 Human GE 8×60K Microarray, Agilent Technologies) by using two-colour detection mode. Production of MMP and TIMP proteins in FLS culture supernatant was evaluated by Human MMP Antibody Array (RayBiotech, Inc., Norcross, USA) and confirmed by ELISA (MMP1, MMP2, and MMP3 purchased from Abcam).

Results:   After adipogenesis induction, transcripts unique to adipocytes (e.g., lipoprotein lipase 4, fatty acid-binding protein 5, fatty acid-binding protein 4, aquaporin 7, perilipin 2, adiponectin, and peroxisome proliferator-activated receptor γ) were clearly induced in FLS, which confirms that adipogenesis was properly induced. Expressions of MMP-1, -2, and -11 transcripts were decreased in FLS following adipogenesis. Conversely, expression of MMP-3 and -25 transcripts was increased by FLS adipogenesis. Consistent with these results, antibody array studies demonstrated that MMP-1 protein production was reduced in FLS culture medium following adipogenesis, whereas MMP-3 protein production increased. Supernatant concentrations of MMP-1 and -2 from FLS obtained from 4 different RA patients were reduced after adipogenesis. The mRNA and protein expression of TIMP-4, a MMP-2 inhibitor, were induced by FLS adipogenesis. 

Conclusion:  Our data demonstrate that MMP-1 and -2 production was inhibited in FLS by adipogenesis induction. If the FLS in pannus were to differentiate into adipocytes with reduced IL-6 and MMPs, the adipocytes would be a more physiological component that would produce fewer pathogenic molecules in the joint. Specifically, the strategy of inducing adipogenesis in FLS may restore both the levels of the harmless cytokine and protease production as well as fat-rich tissue deposition in the affected joint as seen in a normal joint. Further studies are required to include “adipogenesis-induction therapy” in the treatment of RA.


Disclosure:

S. Yamasaki,
None;

K. Kumagai,
None;

K. Endo,
None;

T. Nojima,
None;

E. Sugiyama,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-mmp-in-fibroblast-like-synoviocytes-following-adipogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology